Sensei Biotherapeutics, Inc. (SNSE)

Market Cap	13.05M
Revenue (ttm)	n/a
Net Income (ttm)	-29.67M
Shares Out	25.15M
EPS (ttm)	-1.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	232,756
Open	0.525
Previous Close	0.490
Day's Range	0.490 - 0.525
52-Week Range	0.384 - 1.940
Beta	0.06
Analysts	Strong Buy
Price Target	4.33 (+734.3%)
Earnings Date	Nov 19, 2024

About SNSE

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company’s Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company’s pip...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 2021
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: SNSE
• Website: https://www.senseibio.com

Analyst Forecast

According to 3 analysts, the average rating for SNSE stock is "Strong Buy." The 12-month stock price forecast is $4.33, which is an increase of 734.30% from the latest price.

Price Target

$4.33

(734.30% upside)

Analyst Consensus: Strong Buy